Filgotinib Effective for UC, Study Shows

  From July 2-3 and 8-10, 2021, the European Crohn's and Colitis Organisation (ECCO) held its 2021 virtual Annual Congress (ECCO'21). During the Congress, many discussed new research and trends…

Continue Reading Filgotinib Effective for UC, Study Shows

Anavex 2-73 Improves PD Symptoms, Study Says

Initially, biopharmaceutical company Anavex Life Sciences ("Anavex") developed Anavex 2-73 (blarcamesine) for patients with Alzheimer's disease. Now, the company has expanded its exploration of the therapy to determine its efficacy…

Continue Reading Anavex 2-73 Improves PD Symptoms, Study Says

Study: NUPLAZID as a Treatment for Parkinson’s Disease

ACADIA Pharmaceuticals has released data on NUPLAZID, a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. This treatment is meant to treat Parkinson's disease patients, specifically the delusions…

Continue Reading Study: NUPLAZID as a Treatment for Parkinson’s Disease